New attack on ovarian cancer: Triple-Threat therapy tested
NCT ID NCT03734692
Summary
This study is testing a new combination treatment for ovarian cancer that has returned after initial therapy. It involves delivering chemotherapy and an immune-boosting drug directly into the abdomen, along with an IV immunotherapy drug. The goal is to see if this intensive approach can shrink tumors and control the disease for a longer period in 24 eligible patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.